Abstract
Purpose :
To report mid-term outcomes of Boston Keratoprosthesis type II at a reference center in Spain.
Methods :
This retrospective chart review included medical records of patients who underwent Boston Keratoprosthesis type II surgery at Cruces University Hospital from May 2016 through May 2021. The parameters analyzed were visual acuity, retention, complications and their management.
Results :
A total of 9 eyes in 9 patients received this device during the study period. The most common indication for implantation was severe Sjögren’s syndrome (33.3%) followed by graft vs. host disease (22.2%). The mean follow-up was 2.4 years (± 1.65). Visual acuity improved to better than or equal to 20/40 in 8 eyes (88.8%) and 20/25 in 5 eyes (55.5%), while a BCVA of 20/20 was achieved in 4 eyes (44.4%). At the last visit, device retention and maximum visual acuity were maintained in eight patients. The most common postoperative complication was retroprosthetic membrane formation (66.6%). New-onset glaucoma was detected in two patients (22.2%) both of whom had graft vs. host disease. Device extrusion occurred in one eye, cystoid macular edema was observed in two patients and one case of sterile vitritis was successfully managed. All except one of the patients are on postoperative treatment with systemic immunosuppressants.
Conclusions :
The Boston type II Keratoprosthesis is a useful option for visual rehabilitation in end-stage ocular surface diseases. Multidisciplinary management of complications is of vital importance for the maintenance of vision and the device. Immunosuppressive treatment helps control the inflammation that leads to most associated complications.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.